ARALAB

EPHORAN Multi-Imaging Solutions is a Contract Research Organization providing imaging expertise and knowledge to study, develop and promote the application of imaging technologies in preclinical drug research and development.

EPHORAN provides the opportunity to apply a translational pharmacological approach in drug R&D, evaluating in animal models a molecular-based proof of biological activity and mechanism of action, and translating it into the clinical setting. All the Techniques extensively employed in the clinical setting(e.g. PET, CT, SPECT, MRI, US and in Optical Imaging, both visible light and Near Infra Red) are available.

EPHORAN fosters the development of diagnostic tools, reagents and methodologies for experimental imaging and makes the drug development faster and more cost effective. Pharmaceutical companies will take advantage from its preclinical imaging technologies to carry on more effectively their R&D projects in different therapeutic such as oncology, cardiovascular and CNS. The application of Imaging techniques allows a significant reduction of the time-to-market of novel compounds. Other users that will benefit from access to Ephoran’s services are Researchers from academic and research institution.

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,700 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.

Oroxcell is an independent research organization (CRO) offering research services assessing the safety, toxicity and efficacy of active ingredients and finished formulations.

Specialized in in-vitro testing, particularly in 3D Human Models, Oroxcell is developing its business on two fronts:

• Safety & efficacy testing: From screening to GLP Compliant studies, we provide well established In-vitro platform, 2D and 3D models, for performing routine and regulatory safety testing, ADME (Absorption, Distribution, Metabolism, and Elimination) and Toxicity (sensitization, phototoxicity and genotoxicity) tests, bioanalytical studies, for evaluating pharmaceuticals, medical devices, cosmetics, nutraceuticals, home care and chemical products.

• Research & Innovation: Oroxcell provides a wide range of services including R&D project management and technical support, international consortium setup and management and regulatory & toxicology consulting.
We assist you in selecting or developing the best alternative testing methods for your safety and efficacy issues.

Oroxcell has been certified GLP compliant (Grade A, the highest grade) since 2011 by the French National Medicines and Cosmetics Safety Agency, ANSM.


Website: http://www.oroxcell.com
Contact: contact@oroxcell.com

Medfiles is a dynamic Scandinavian & Baltics CRO established in 1987 that supports its clients on the path of commercialization with an array of services related to human and veterinary medicines.

With a team of over 150 experts, Medfiles provides services in R&D and Analytics, Regulatory Affairs, Clinical research and via Health economics, we cover Pricing & Reimbursement as well as budget impact modelling for several local & global markets. With strong investments in electronic centralized Regulatory and Safety tools, Medfiles has the capability of providing a wider range of services under one roof to its clients that are based in the EU or outside of it and via our strategic partnerships, we extend our capabilities and reach to a network of over 80 countries.

Our client base is varied but includes both small and large Pharma, Biotech, Medical device, Veterinary, Public health authorities, CMO & CROs. To work with Medfiles, means you work with a company that has over 30 years of experience and a long list of International clients & references to prove its worth. Besides Nordic and Baltic countries, Medfiles servers European and Asian countries and the United states. In addition to our international expertise, we have CRO network partners and sister companies in Japan, India, and the United States which support our efforts globally.

Our driving values in all business are Flexibility, Fairness and Freshness. These are the cornerstones of our way of operation and collaboration. Our mission is to develop more efficient, safer, and cost-effective health care products with quality. We aim to create better and healthier future together. Our vision is to strengthen our position as the leading CRO in Finland, and the Nordic and Baltic countries – by being a “one-stop-shop”.

Medfiles is a company that solidly supports its clients through a large offering of services that meets the ever- evolving requirements of the Healthcare Industry. Speak to an expert today!

3H Biomedical is an innovative life-science company that discovers, develops and distributes human cell-based products and technologies for life science research, drug development and tissue engineering. We take pride in our contribution to improving human health and environment.

Our mission is to help scientists be more productive, more competitive and more innovative.

Serving the global research community, biotech sector and pharmaceutical industry. We supply more than 260 different types of primary human cells, media and cell-based products.

R&D projects:

EUROSTARS: PREVAIL
Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer. The PREVAIL project will deliver a first-in-class targeted therapeutic for treatment of triple negative breast cancer (TNBC).


SEAL OF EXCELLENCE

Next generation of targeted dendritc cell vaccine for cancer treatment, a therapeutic cancer vaccine technology platform.

We are actively seeking partners in the pharmaceutical industry and clinical centres in order to co-develop our patented vaccine technology.